Previous 10 | Next 10 |
BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models -Preclinical findings that demonstrated efficacy in non...
BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 PR Newswire PALO ALTO, Calif. , Oct. 6, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmac...
BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants - Data presented at American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meetin...
Halvorsen's 13F portfolio value decreased marginally from $33.58B to $32.98B this quarter. The number of positions decreased from 94 to 88. Viking Global added FIGS Inc. & JD.com and increased Amazon.com & General Electric during the quarter. The top three positions are Am...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated. 6 stocks were removed and 6 added from the univ...
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) - If successful, BridgeBio's drug could be the first approved therapy for patients with LGMD2i - BridgeBio's investigational ...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings the consensus holdings were updated, 6 stocks were removed and 6 added from the un...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the univ...
LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients wi...
Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holds 48...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...